NCT07458906
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +10 more
- Locations
-
- The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China
Clinical trial condition
DLL3-expressing Tumors
Explore clinical trials studying DLL3-expressing Tumors. Study availability and eligibility vary by location and protocol.
2 public trials
1 recruiting study
DLL3-expressing Tumors trial results
Active, not recruiting
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
NCT06788938
- Conditions
- Advanced Tumors, DLL3-expressing Tumors, Neoplasms
- Locations
-
- UC Davis Comprehensive Cancer Center Davis, California, United States
- UCI Health Chao Family Comprehensive Cancer Center Irvine, California, United States
- University of California at Los Angeles Los Angeles, California, United States
- UC San Diego Moores Cancer Center San Diego, California, United States